ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress

MOUNTAIN VIEW, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., CCXI, today announced two upcoming presentations during the 55th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, being held in collaboration with the Danish Society of Nephrology (DSN) from May 24-27, 2018 in Copenhagen, Denmark.

Presentation Information:

Abstract Title: Adverse Events with Glucocorticoid Standard of Care Versus Avacopan in ANCA-Associated Vasculitis: Observations from the CLEAR Trial

Session Title: Category: I - Glomerulonephritis

Poster Presentation Date & Time: : Friday, May 25, 2018, 9:30 a.m. – 10:45 a.m. CEST

Authors: David Jayne, Peter Merkel, Antonia Potarca, Thomas Schall, Jan Hillson, Jun Deng, Pirow Bekker

Location: Poster Area, Bella Center, Coppenhagen, Denmark

Abstract Title: CCR2 Inhibition Improves Renal Function and Normalizes Glomerular Structure in Focal Segmental Glomerulosclerosis (FSGS) Models

Session Title: Free Communication Session: Glomerulonephritis 2

Oral Presentation Date & Time: Saturday, May 26, 2018, 5:35 p.m. CEST

Authors: Zhenhua Miao, Linda Ertl, Xiaoping Zang, Bin Zhao, Dale Newland, James Campbell, Jeffrey McMahon, Xiaoli Liu, Ton Dang, Simon Yau, Shichang Miao, Penglie Zhang, Israel Charo, Thomas Schall, Rajinder Singh

Location: Hall A3, Bella Center, Coppenhagen, Denmark

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare diseases, avacopan (CCX168) and CCX140.

Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated Vasculitis). In clinical studies to date, avacopan was shown to be safe and well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for ANCA-associated Vasculitis, C3G and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.

The Company's other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease.

ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China.

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya

Executive Vice President,

Chief Financial and Administrative Officer

investor@chemocentryx.com

Media:

Stephanie Tomei

408.234.1279

media@chemocentryx.com

Investors:

Steve Klass, Burns McClellan

212.213.0006                

sklass@burnsmc.com